Moderna, Inc. (MRNA)
Should You Buy This Stock After a Regulatory Setback?
Moderna's leading non-COVID candidate won't earn approval when the biotech hoped. However, the delay should be a relatively short one if we believe the word of regulators.
Vaccine Stocks Rise on Growing Threat of Bird Flu Infections
The Biden administration is reportedly in talks with vaccine makers Moderna (MRNA) and Pfizer (PFE) to develop bird flu vaccines over increasing fears of widespread transmission of the infection.
The Moderna News That Has MRNA Stock Price Surging This Week: 3 Key Catalysts
Moderna (NASDAQ: MRNA ) stock is up more than 20% in just the past five trading sessions as investors foresee strong growth opportunities for the biotechnology firm. Indeed, the company has climbed 44% so far this year as one of the big winners of 2024's bull market.
The Moderna News That Has MRNA Stock Price Surging: 3 Key Catalysts
Moderna (NASDAQ: MRNA ) stock is up more than 20% in just the past five trading sessions as investors foresee strong growth opportunities for the biotechnology firm. Indeed, the company has climbed 44% so far this year as one of the big winners of 2024's bull market.
Moderna Has Big AI News. Is the Stock a Buy?
Moderna has been using artificial intelligence (AI) for years to save precious time in the laboratory. But the biotech isn't stopping there.
Moderna wins case in patent dispute with Pfizer, BioNTech over COVID shot, FT reports
Moderna has won a case at the European Patent Office in its dispute with Pfizer and BioNTech over its COVID-19 vaccine, the Financial Times reported on Friday.
